Text Size

Characteristics and Utility of Fluorescein Breakup Patterns among Dry Eyes in Clinic-Based Settings

Shigeyasu C., Yamada M., Yokoi N., Kawashima M., Suwaki K., Uchino M., Hiratsuka Y., Tsubota K.

  • 2020
  • Diagnostics
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, 1818611, Japan; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, 6020841, Japan; Department of Ophthalmology, Keio University School of Medicine, Tokyo, 1608582, Japan; Santen Pharmaceutical Co., Ltd., Osaka, 5308552, Japan; Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, 1138431, Japan; Tsubota Laboratory, Inc., Tokyo, 1600016, Japan

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022